Who Actually Needs GLP-1 Therapy: PlexusDx Assessment Approach PlexusDx compounded semaglutide injection (at $189/mo month-to-month, or from $149/mo on the 6-month plan) is intended for individuals with a BMI of 27 or higher, or those with obesity-related conditions like type 2 diabetes, heart disease, or prediabetes
Patients should avoid initiating multiple new skincare products simultaneously, as this makes it difficult to identify beneficial versus problematic interventions
These usually occur during the initial dose increase phase and often subside within a month
A crowded semaglutide biosimilars pipeline is shaping up in Mainland China *Biosimilars of semaglutide include both T2D and obesity patient segments (April 2024) Source: Clarivate Cortellis In a three-way battle, will price beat innovation
Avoid EDTA, DTPA, or other strong chelators in buffer systems as they will strip copper from the complex
Semaglutide is eliminated primarily through peptide degradation and glomerular filtration, not hepatic metabolism, which means it does not compete with HRT for liver enzyme systems like cytochrome P450
